Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2022 Nov 16

PMID 36381085

Authors

Peilin Xie

Bilian Yao

Dao Huang

Yongyan Chen

Qiming Gong

Xinxin Zhang

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Monocyte/macrophage-associated CD163 is an indicator of the severity of liver inflammation and cirrhosis, but the difference of soluble CD163 (sCD163) levels in chronic hepatitis B (CHB) patients and hepatitis B surface antigen (HBsAg)-loss patients is unclear. Herein, we aimed to compare the sCD163 levels in CHB patients and HBsAg-loss patients with or without antiviral treatment.

Methods: sCD163 and CD163 expression on monocytes were compared among four groups, healthy subjects, treatment-naïve CHB patients, spontaneous HBsAg-loss patients, and treatment-related HBsAg-loss patients. The correlation between sCD163 levels and clinical parameters in CHB patients was analyzed. A group of 80 patients with hepatitis B virus (HBV) infection and liver biopsy were recruited.

Results: sCD163 levels were higher in the CHB group than in the other three groups. sCD163 levels were higher in treatment-related HBsAg-loss patients than in spontaneous HBsAg-loss patients. sCD163 levels were negatively correlated with hepatitis B e-antigen (HBeAg) and HBsAg levels in HBeAg-positive patients. Liver biopsy results further demonstrated that sCD163 levels were elevated in CHB patients with substantial inflammation (A≥2) or fibrosis (F≥2). The sCD163 model was more sensitive in predicting inflammation than other noninvasive models. Its levels were higher in patients with normal alanine aminotransferase levels and significant inflammation (A≥2) than in patients with no or mild inflammation.

Conclusions: sCD163 and CD163 expression on monocytes were associated with CHB inflammation and HBsAg loss, and may be used as markers to predict HBV-specific immune activation.

Citing Articles

Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation.

Tang J, Zhang J, Zhang G, Peng W, Ling N, Zhou Y mBio. 2024; 15(4):e0306823.

PMID: 38440978 PMC: 11005361. DOI: 10.1128/mbio.03068-23.

References

Sherman K, Meeds H, Rouster S, Abdel-Hameed E, Hernandez J, Tamargo J . Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis. Open Forum Infect Dis. 2021; 8(6):ofab203. PMC: 8180248. DOI: 10.1093/ofid/ofab203. View

Tan A, Koh S, Bertoletti A . Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015; 5(8):a021428. PMC: 4526720. DOI: 10.1101/cshperspect.a021428. View

Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T . Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat. 2014; 22(4):427-32. DOI: 10.1111/jvh.12309. View

Davis B, Zarev P . Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom. 2004; 63(1):16-22. DOI: 10.1002/cyto.b.20031. View

Ye H, Wang L, Zhao J, Wang K . Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure. World J Gastroenterol. 2013; 19(18):2818-25. PMC: 3653157. DOI: 10.3748/wjg.v19.i18.2818. View

Bert N, Gill U, Hong M, Kunasegaran K, Tan D, Ahmad R . Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology. 2020; 159(2):652-664. DOI: 10.1053/j.gastro.2020.04.019. View

Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T . Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020; 73(2):409-422. DOI: 10.1016/j.jhep.2020.04.013. View

Laursen T, Wong G, Kazankov K, Sandahl T, Moller H, Hamilton-Dutoit S . Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. J Gastroenterol Hepatol. 2017; 33(2):484-491. DOI: 10.1111/jgh.13849. View

Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S . Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012; 143(4):963-73.e9. DOI: 10.1053/j.gastro.2012.07.014. View

10.

Li Q, Zhou Y, Huang C, Li W, Chen L . A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. Sci Rep. 2018; 8(1):15449. PMC: 6193950. DOI: 10.1038/s41598-018-33412-z. View

11.

Schaer D, Schaer C, Buehler P, Boykins R, Schoedon G, Alayash A . CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood. 2005; 107(1):373-80. DOI: 10.1182/blood-2005-03-1014. View

12.

Auffray C, Sieweke M, Geissmann F . Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009; 27:669-92. DOI: 10.1146/annurev.immunol.021908.132557. View

13.

Zawada A, Rogacev K, Rotter B, Winter P, Marell R, Fliser D . SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood. 2011; 118(12):e50-61. DOI: 10.1182/blood-2011-01-326827. View

14.

Krijgsman D, de Vries N, Andersen M, Skovbo A, Tollenaar R, Moller H . CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood. Int J Mol Sci. 2020; 21(16). PMC: 7460610. DOI: 10.3390/ijms21165925. View

15.

Kristiansen M, Graversen J, Jacobsen C, Sonne O, Hoffman H, Law S . Identification of the haemoglobin scavenger receptor. Nature. 2001; 409(6817):198-201. DOI: 10.1038/35051594. View

16.

Bertoletti A, Ferrari C . Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2011; 61(12):1754-64. DOI: 10.1136/gutjnl-2011-301073. View

17.

Gronbaek H, Rodgaard-Hansen S, Aagaard N, Arroyo V, Moestrup S, Garcia E . Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol. 2015; 64(4):813-22. DOI: 10.1016/j.jhep.2015.11.021. View

18.

Tsounis E, Tourkochristou E, Mouzaki A, Triantos C . Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021; 27(21):2727-2757. PMC: 8173382. DOI: 10.3748/wjg.v27.i21.2727. View

19.

Raveney B, Copland D, Calder C, Dick A, Nicholson L . TNFR1 signalling is a critical checkpoint for developing macrophages that control of T-cell proliferation. Immunology. 2010; 131(3):340-9. PMC: 2996554. DOI: 10.1111/j.1365-2567.2010.03305.x. View

20.

Boltjes A, Movita D, Boonstra A, Woltman A . The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014; 61(3):660-71. DOI: 10.1016/j.jhep.2014.04.026. View